ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.
ARS Pharmaceuticals chief executive Richard Lowenthal said the company is “very surprised” and “deeply disappointed” by the FDA’s decision.